Abstract
IN BRIEF
This article reviews the history of phlorizin, the role of the kidney in glucose regulation, and the modulation of that regulatory system via pharmacological means. It also offers a discussion of the results of clinical trials of the most salient sodium glucose co-transporter inhibitor to date: dapagliflozin.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献